Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Autolus Therapeutics (AUTL) over the last 6 years, with Dec 2024 value amounting to -$0.86.

  • Autolus Therapeutics' EPS (Weighted Average and Diluted) rose 3.23% to -$0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.83, marking a year-over-year increase of 31.97%. This contributed to the annual value of -$0.86 for FY2024, which is 28.33% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' EPS (Weighted Average and Diluted) is -$0.86, which was up 28.33% from -$1.20 recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.86 in FY2024 and a low of -$2.76 during FY2020.
  • Over the past 3 years, Autolus Therapeutics' median EPS (Weighted Average and Diluted) value was -$1.20 (recorded in 2023), while the average stood at -$1.21.
  • Data for Autolus Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY climbed of 28.62% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Autolus Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.76 in 2020, then rose by 28.62% to -$1.97 in 2021, then rose by 20.30% to -$1.57 in 2022, then increased by 23.57% to -$1.20 in 2023, then grew by 28.33% to -$0.86 in 2024.